Analysis of schizophrenia and hepatocellular carcinoma genetic network with corresponding modularity and pathways: Novel insights to the immune system

BMC Genomics

Volumn 14, Issue , 2013, Pages

  Huang, Kuo Chuan ^a,b   Yang, Ko Chun ^a   Lin, Han ^a   Tsun Hui, Theresa Tsao ^a   Lee, Wen Kuei ^b   Lee, Sheng An ^c   Kao, Cheng Yan ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c KAINAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; CETUXIMAB; DASATINIB; DIENESTROL; ESTROGEN; ESTRONE; FLAVOPIRIDOL; FULVESTRANT; IMMUNOGLOBULIN; INDOLOCARBAZOLE; INTERLEUKIN 2; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; LIOTHYRONINE; MEVINOLIN; NORELGESTROMIN; PIPERAZINE ESTRONE SULFATE; PROTEIN KINASE C INHIBITOR; RETINOIC ACID; RETINOL; RITUXIMAB; TAMIBAROTENE; TAZAROTENE; THYMOCYTE ANTIBODY; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC CORRELATION; IMMUNE RESPONSE; IMMUNE SYSTEM; LCK GENE; LIVER CELL CARCINOMA; PROTEIN PROTEIN INTERACTION; RARA GENE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SIRPB1 GENE; SYK GENE; CELL CYCLE; FOOD AND DRUG ADMINISTRATION; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; HUMAN; LIVER TUMOR; METABOLISM; PATHOLOGY; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DATABASES, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; LIVER NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; SCHIZOPHRENIA; TRETINOIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VITAMIN A;

EID: 84908179132     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-S5-S10     Document Type: Article

References (84)

1. Muller N, Schwarz MJ: Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev Neurother 2006, 6:1017-1038
2. Muller N, Schwarz MJ: [Immunology in schizophrenic disorders]. Nervenarzt 2007, 78:253-256, 258-260, 262-253
3. Richard MD, Brahm NC: Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am J Health Syst Pharm 2012, 69:757-766
4. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L: Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008, 40:827-834
5. Sun J, Kuo PH, Riley BP, Kendler KS, Zhao Z: Candidate genes for schizophrenia: a survey of association studies and gene ranking. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1173-1181
6. Sun J, Han L, Zhao Z: Gene-and evidence-based candidate gene selection for schizophrenia and gene feature analysis. Artif Intell Med 2010, 48:99-106
7. Sun J, Jia P, Fanous AH, van den Oord E, Chen X, Riley BP, Amdur RL, Kendler KS, Zhao Z: Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS One 2010, 5: e11351
8. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, Winiger E, Breier A, Shekhar A, Amdur R, et al: Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 2012, 17:887-905
9. Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D, Capdevielle D: Antipsychotic drugs: pro-cancer or anti-cancer? A systematic review. Med Hypotheses 2012, 79:38-42
10. Jablensky A, Lawrence D: Schizophrenia and cancer: is there a need to invoke a protective gene? Arch Gen Psychiatry 2001, 58:579-580
11. Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D: Reduced cancer incidence among patients with schizophrenia. Cancer 2005, 104:2817-2821
12. Mortensen PB: The incidence of cancer in schizophrenic patients. J Epidemiol Community Health 1989, 43:43-47
13. Lin GM, Chen YJ, Kuo DJ, Jaiteh LE, Wu YC, Lo TS, Li YH: Cancer Incidence in Patients With Schizophrenia or Bipolar Disorder: A Nationwide Population-Based Study in Taiwan, 1997-2009. Schizophr Bull 2011
14. Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X: Incidence of Cancer in Patients With Schizophrenia and Their First-Degree Relatives: A Population-Based Study in Sweden. Schizophr Bull 2012
15. Gal G, Goral A, Murad H, Gross R, Pugachova I, Barchana M, Kohn R, Levav I: Cancer in parents of persons with schizophrenia: is there a genetic protection? Schizophr Res 2012, 139:189-193
16. Hodgson R, Wildgust HJ, Bushe CJ: Cancer and schizophrenia: is there a paradox? J Psychopharmacol 2010, 24:51-60
17. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57
18. Kanehisa M: The KEGG database. Novartis Found Symp 2002, 247:91-101, discussion 101-103, 119-128, 244-152
19. Kamburov A, Stelzl U, Lehrach H, Herwig R: The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res 2013, 41:D793-800
20. Barnes MR, Huxley-Jones J, Maycox PR, Lennon M, Thornber A, Kelly F, Bates S, Taylor A, Reid J, Jones N, et al: Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia. J Neurosci Res 2011, 89:1218-1227
21. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010, 70:10202-10212
22. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180
23. Bader GD, Donaldson I, Wolting C, Ouellette BF, Pawson T, Hogue CW: BIND-The Biomolecular Interaction Network Database. Nucleic Acids Res 2001, 29:242-245
24. Goel R, Harsha HC, Pandey A, Prasad TS: Human Protein Reference Database and Human Proteinpedia as resources for phosphoproteome analysis. Mol Biosyst 2012, 8:453-463
25. Cesareni G, Chatr-aryamontri A, Licata L, Ceol A: Searching the MINT database for protein interaction information. Curr Protoc Bioinformatics 2008, Chapter 8:Unit 8 5
26. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas N, O'Donnell L, et al: The BioGRID interaction database: 2013 update. Nucleic Acids Res 2013, 41:D816-823
27. Xenarios I, Salwinski L, Duan XJ, Higney P, Kim SM, Eisenberg D: DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res 2002, 30:303-305
28. Lee SA, Chan CH, Chen TC, Yang CY, Huang KC, Tsai CH, Lai JM, Wang FS, Kao CY, Huang CY: POINeT: protein interactome with sub-network analysis and hub prioritization. BMC Bioinformatics 2009, 10:114
29. Zheng S, Zhao Z: GenRev: exploring functional relevance of genes in molecular networks. Genomics 2012, 99:183-188
30. Ma Q, Chirn GW, Cai R, Szustakowski JD, Nirmala NR: Clustering protein sequences with a novel metric transformed from sequence similarity scores and sequence alignments with neural networks. BMC Bioinformatics 2005, 10:114
31. Chen TC, Lee SA, Chan CH, Juang YL, Hong YR, Huang YH, Lai JM, Kao CY, Huang CY: Cliques in mitotic spindle network bring kinetochoreassociated complexes to form dependence pathway. Proteomics 2009, 9:4048-4062
32. Jupe S, Akkerman JW, Soranzo N, Ouwehand WH: Reactome-a curated knowledgebase of biological pathways: megakaryocytes and platelets. J Thromb Haemost 2012
33. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH: PID: the Pathway Interaction Database. Nucleic Acids Res 2009, 37: D674-679
34. Kamburov A, Pentchev K, Galicka H, Wierling C, Lehrach H, Herwig R: ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res 2011, 39:D712-717
35. Sreenivasaiah PK, Rani S, Cayetano J, Arul N, Kim do H: IPAVS: Integrated Pathway Resources, Analysis and Visualization System. Nucleic Acids Res 2012, 40:D803-808
36. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, et al: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011, 39:D1035-1041
37. Ruepp A, Waegele B, Lechner M, Brauner B, Dunger-Kaltenbach I, Fobo G, Frishman G, Montrone C, Mewes HW: CORUM: the comprehensive resource of mammalian protein complexes-2009. Nucleic Acids Res 2010, 38:D497-501
38. Zhao M, Sun J, Zhao Z: TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res 2013, 41:D970-976
39. Catts VS, Catts SV: Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res 2000, 41:405-415
40. Cui DH, Jiang KD, Jiang SD, Xu YF, Yao H: The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia. Mol Psychiatry 2005, 10:669-677
41. Aoki K, Taketo MM: Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 2007, 120:3327-3335
42. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W: Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283
43. Shiota S, Tochigi M, Shimada H, Ohashi J, Kasai K, Kato N, Tokunaga K, Sasaki T: Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a Japanese population. J Hum Genet 2008, 53:929-935
44. Aberg KA, Liu Y, Bukszar J, McClay JL, Khachane AN, Andreassen OA, Blackwood D, Corvin A, Djurovic S, Gurling H, et al: A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry 2013, 70:1-9
45. Yang Y, Xiao Z, Chen W, Sang H, Guan Y, Peng Y, Zhang D, Gu Z, Qian M, He G, et al: Tumor suppressor gene TP53 is genetically associated with schizophrenia in the Chinese population. Neurosci Lett 2004, 369:126-131
46. Lee SA, Tsao TT, Yang KC, Lin H, Kuo YL, Hsu CH, Lee WK, Huang KC, Kao CY: Construction and analysis of the protein-protein interaction networks for schizophrenia, bipolar disorder, and major depression. BMC Bioinformatics 2011, 12(Suppl 13):S20
47. Yin F, Liu X, Li D, Wang Q, Zhang W, Li L: Tumor suppressor genes associated with drug resistance in ovarian cancer (Review). Oncol Rep 2013, 30:3-10
48. Guan X, Wang LE, Liu Z, Sturgis EM, Wei Q: Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. J Cell Mol Med 2013
49. Pagano M: Cell cycle regulation by the ubiquitin pathway. FASEB J 1997, 11:1067-1075
50. Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H, Tempst P, de Murcia G, Evans R, Chambon P, Reinberg D: PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell 2005, 18:83-96
51. Specenier P, Vermorken JB: Cetuximab: its unique place in head and neck cancer treatment. Biologics 2013, 7:77-90
52. Arnold D, Stein A: New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy. Drugs 2013, 73:883-891
53. Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, et al: Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. Ann Hematol 2013
54. Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63:803-843
55. Noguchi T, Ritter G, Nishikawa H: Antibody-based therapy in colorectal cancer. Immunotherapy 2013, 5:533-545
56. Connolly R, Nguyen NK, Sukumar S: Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway In Cancer Prevention and Treatment. Clin Cancer Res 2013
57. Smith W, Saba N: Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol 2005, 55:143-152
58. Carrera S, Cuadrado-Castano S, Samuel J, Jones GD, Villar E, Lee SW, Macip S: Stra6, a retinoic acid-responsive gene, participates in p53-induced apoptosis after DNA damage. Cell Death Differ 2013
59. Wan C, Shi Y, Zhao X, Tang W, Zhang M, Ji B, Zhu H, Xu Y, Li H, Feng G, He L: Positive association between ALDH1A2 and schizophrenia in the Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1491-1495
60. Wan C, Yang Y, Li H, La Y, Zhu H, Jiang L, Chen Y, Feng G, He L: Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res 2006, 5:3213-3216
61. Jones AL, Mowry BJ, Pender MP, Greer JM: Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol 2005, 83:9-17
62. Fineberg AM, Ellman LM: Inflammatory Cytokines and Neurological and Neurocognitive Alterations in the Course of Schizophrenia. Biol Psychiatry 2013
63. Frydecka D, Beszlej A, Karabon L, Pawlak-Adamska E, Tomkiewicz A, Partyka A, Jonkisz A, Monika SB, Kiejna A: The role of genetic variations of immune system regulatory molecules CD28 and CTLA-4 in schizophrenia. Psychiatry Res 2013
64. Ferentinos P, Dikeos D: Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry 2012, 25:381-390
65. Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA: Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res 2013
66. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, Turck CW: Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009, 259:151-163
67. Rossy J, Owen DM, Williamson DJ, Yang Z, Gaus K: Conformational states of the kinase Lck regulate clustering in early T cell signaling. Nat Immunol 2013, 14:82-89
68. Trevillyan JM, Chiou XG, Ballaron SJ, Tang QM, Buko A, Sheets MP, Smith ML, Putman CB, Wiedeman P, Tu N, et al: Inhibition of p56(lck) tyrosine kinase by isothiazolones. Arch Biochem Biophys 1999, 364:19-29
69. Nyakeriga AM, Garg H, Joshi A: TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues. Cytometry A 2012, 81:797-805
70. Yan Q, Barros T, Visperas PR, Deindl S, Kadlecek TA, Weiss A, Kuriyan J: Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker. Mol Cell Biol 2013
71. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS: Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013, 18:206-214
72. Huang TL: Effects of antipsychotics on the BDNF in schizophrenia. Curr Med Chem 2013, 20:345-350
73. Xu MQ, St Clair D, Feng GY, Lin ZG, He G, Li X, He L: BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008, 18:449-457
74. Muglia P, Vicente AM, Verga M, King N, Macciardi F, Kennedy JL: Association between the BDNF gene and schizophrenia. Mol Psychiatry 2003, 8:146-147
75. Zhang XY, Liang J, Chen da C, Xiu MH, Yang FD, Kosten TA, Kosten TR: Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl) 2012, 222:277-284
76. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ: Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011, 16:960-972
77. Kantrowitz JT, Javitt DC: N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 2010, 83:108-121
78. Snyder MA, Gao WJ: NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci 2013, 10:114
79. Favalli G, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis ZJ: The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res 2012, 46:1-11
80. Yamada K, Iwayama Y, Hattori E, Iwamoto K, Toyota T, Ohnishi T, Ohba H, Maekawa M, Kato T, Yoshikawa T: Genome-wide association study of schizophrenia in Japanese population. PLoS One 2011, 6:e20468
81. Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M: Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer 2012, 75:110-118
82. Liu L, Chen X, Xie S, Zhang C, Qiu Z, Zhu F: Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicininduced apoptosis by inhibiting p53 activation. Hepatology 2012, 56:1760-1769
83. Xie C, Wang W, Yang F, Wu M, Mei Y: RUVBL2 is a novel repressor of ARF transcription. FEBS Lett 2012, 586:435-441
84. Li K, Ma Q, Shi L, Dang C, Hong Y, Wang Q, Li Y, Fan W, Zhang L, Cheng J: NS5ATP9 gene regulated by NF-kappaB signal pathway. Arch Biochem Biophys 2008, 479:15-19